<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518268</url>
  </required_header>
  <id_info>
    <org_study_id>0124-18-TLV</org_study_id>
    <nct_id>NCT03518268</nct_id>
  </id_info>
  <brief_title>Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor</brief_title>
  <official_title>The Efficacy of the Probiotic Supplement Vivomixx on Prevention of Bone Loss in Early Menopausal Women With Breast Cancer Treated With an Aromatase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of the probiotic food supplement Vivomixx in the prevention
      of bone loss occurring in post menopausal women with breast cancer treated with an aromatase
      inhibitor. Half of the participants will receive Vivomixx while the other half will receive a
      placebo. The primary endpoint is to assess changes of bone turnover markers during the period
      of 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aromatase inhibitors function to reduce estrogen levels. They are considered first-line
      treatment for postmenopausal women with estrogen receptor-positive breast cancer. Estrogen
      depletion leads to significant loss of bone mineral density and an increased fracture risk.
      One contributing mechanism to &quot;estrogen deficiency associated bone loss&quot; is the increase in
      systemic and local gut inflammatory responses upon estrogen deficiency. Probiotics have been
      shown to decrease inflammatory cytokine formation in both the systemic circulation and gut.

      Vivomixx is a high potency probiotic medical food designated for the dietary management of
      inflammatory gut conditions in adults and children and is currently being studied in clinical
      trials in a wide variety of inflammatory conditions such as asthma and diabetes. In
      preclinical studies Vivomixx has been shown to protect from estrogen deficient bone loss.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collagen type 1 cross-linked C-telopeptide (CTX)</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in CTX in serum compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum type 1 procollagen (N-terminal) P1NP</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in serum in P1NP compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase/ bone specific alkaline phosphatase</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in alkaline phosphatase/ bone specific alkaline phosphatase in serum compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in osteocalcin in serum compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sclerostin</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in sclerostin in serum compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-necrosis factor-alpha</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in tumor-necrosis factor-alpha in serum compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-17</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in interleukin-17 in serum compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor activator of nuclear factor kappa B ligand (RANK-ligand)</measure>
    <time_frame>3-6 months</time_frame>
    <description>Change in percent in RANK-ligand in serum compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis, Osteopenia</condition>
  <arm_group>
    <arm_group_label>Dietary supplement Vivomixx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vivomixx sachets contains a mixture of 450 billion viable lyophilized bacteria from 8 strains: Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgaricus DSM 24734, Bifidobacterium longum DSM 3 24736, Bifidobacterium infantis DSM 24737, Bifidobacterium breve DSM 24732, and Streptococcus thermophilus DSM 24731</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo sachets contain the inactive ingredients maltose and silicon dioxides</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivomixx</intervention_name>
    <description>The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months</description>
    <arm_group_label>Dietary supplement Vivomixx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The intervention consists of 2 sachets a day of placebo, for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt;40 years

          2. Breast cancer stages 1-3 (non metastatic)

          3. Under treatment with aromatase inhibitors for at least 30 days

          4. In menopausal status for ≤5y

          5. Estrogen receptor positive tumor

          6. CTX ≥400 pg/ml

        Exclusion Criteria:

          1. Distant metastases

          2. Additional primary malignancy

          3. Metabolic bone disease (hyperparathyroidism, hyperthyroidism, pagets etc)

          4. Glucocorticoid treatment (chronic or high dose &gt;7.5 mg in the last three months)

          5. Past bisphosphonate treatment

          6. Bone densitometry (DXA) T-Score &lt;-2

          7. Lactose intolerant subjects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naftali Stern, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sigal Shaklai, M.D, Ph.D</last_name>
    <phone>+972-3-6973732</phone>
    <email>Sigal.shaklai@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Rouach, M.D</last_name>
    <phone>+972-3-6973732</phone>
    <email>vanessar@tlvmc.gov.il</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Deputy Director General for R&amp;D</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>bone mass</keyword>
  <keyword>postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

